EPO and myeloproliferative neoplasm: Although activation of these pathways can partially explain the phenotypes observed in MPN patient cells, such as hypersensitivity to erythropoietin (EPO), it remains unclear how a single mutation can cause three distinct clinical phenotypes in humans [11].